Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group. Dahlén T, et al. Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14. Ann Intern Med. 2016. PMID: 27295519
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T, Kalin M, Cederlund K, Nordlander A, Björkholm M, Ljungman P, Blennow O. Dahlén T, et al. Eur J Haematol. 2016 Feb;96(2):175-80. doi: 10.1111/ejh.12565. Epub 2015 May 6. Eur J Haematol. 2016. PMID: 25880378 Free PMC article.
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
Hirt C, Iannazzo S, Chiroli S, McGarry LJ, le Coutre P, Stenke L, Dahlén T, Lipton JH. Hirt C, et al. Among authors: dahlen t. Appl Health Econ Health Policy. 2019 Aug;17(4):555-567. doi: 10.1007/s40258-019-00489-0. Appl Health Econ Health Policy. 2019. PMID: 31168745
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H, Sandin F, Dahlén T, Dremaine A, Lübking A, Markevärn B, Myhr-Eriksson K, Olsson K, Olsson-Strömberg U, Själander A, Söderlund S, Wennström L, Wadenvik H, Stenke L, Höglund M, Richter J. Flygt H, et al. Among authors: dahlen t. Br J Haematol. 2021 Jun;193(5):915-921. doi: 10.1111/bjh.17392. Epub 2021 Mar 30. Br J Haematol. 2021. PMID: 33782950 Free article.
19 results